Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors

Tamas Alexy, A. Tóth, Zsolt Marton, B. Horváth, Katalin Koltai, G. Fehér, Gabor Kesmarky, T. Kalai, K. Hideg, B. Sümegi, K. Tóth

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pathologic platelet activation has been implicated in the pathogenesis of ischemic heart disease. Since cardiomyocytes can be protected from ischemia-reoxygenation injury by poly(ADP-ribose) polymerase (PARP) inhibitors mimicking the adenine/ADP part of NAD+, their structural resemblance to ADP may also enable the blockade of platelet aggregation via binding to ADP receptors. Blood samples drawn from healthy volunteers were pre-incubated with different concentrations of PARP inhibitors: 4-hydroxyquinazoline, 2-mercapto-4(3H)-quinazolinone, or HO-3089. ADP-, collagen- and epinephrine-induced platelet aggregation was evaluated according to the method described by Born. The effect of PARP inhibitors on thrombocyte aggregation was also examined when platelets were sensitized by heparin and in the presence of incremental concentrations of ADP. All examined PARP inhibitors reduced the ADP-induced platelet aggregation in a dose-dependent manner (significant inhibition at 20 μM for HO-3089 and at 500 μM for the other agents; P <0.05), even if platelets were sensitized with heparin. However, their hindrance on platelet aggregation waned as the concentration of ADP rose (no effect at 40 μM ADP). PARP inhibitors had minimal effect on both collagen- and epinephrine-induced platelet aggregation. Our study first demonstrates the feasibility of a design for PARP inhibitors that does not only protect against ischemia-reperfusion-induced cardiac damage but may also prevent thrombotic events.

Original languageEnglish
Pages (from-to)423-431
Number of pages9
JournalJournal of Cardiovascular Pharmacology
Volume43
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Platelet Aggregation
Adenosine Diphosphate
Blood Platelets
Epinephrine
Heparin
Collagen
Ischemia
Purinergic P2 Receptors
Platelet Activation
Adenine
Poly(ADP-ribose) Polymerase Inhibitors
Cardiac Myocytes
NAD
Reperfusion
Myocardial Ischemia
Healthy Volunteers
Wounds and Injuries

Keywords

  • Antagonists
  • Coronary circulation
  • Platelets
  • Poly(ADP-ribose) polymerase inhibitors
  • Receptors
  • Thrombosis/embolism

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors. / Alexy, Tamas; Tóth, A.; Marton, Zsolt; Horváth, B.; Koltai, Katalin; Fehér, G.; Kesmarky, Gabor; Kalai, T.; Hideg, K.; Sümegi, B.; Tóth, K.

In: Journal of Cardiovascular Pharmacology, Vol. 43, No. 3, 03.2004, p. 423-431.

Research output: Contribution to journalArticle

@article{81acc490efa3425eaa6e9e53f76715e5,
title = "Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors",
abstract = "Pathologic platelet activation has been implicated in the pathogenesis of ischemic heart disease. Since cardiomyocytes can be protected from ischemia-reoxygenation injury by poly(ADP-ribose) polymerase (PARP) inhibitors mimicking the adenine/ADP part of NAD+, their structural resemblance to ADP may also enable the blockade of platelet aggregation via binding to ADP receptors. Blood samples drawn from healthy volunteers were pre-incubated with different concentrations of PARP inhibitors: 4-hydroxyquinazoline, 2-mercapto-4(3H)-quinazolinone, or HO-3089. ADP-, collagen- and epinephrine-induced platelet aggregation was evaluated according to the method described by Born. The effect of PARP inhibitors on thrombocyte aggregation was also examined when platelets were sensitized by heparin and in the presence of incremental concentrations of ADP. All examined PARP inhibitors reduced the ADP-induced platelet aggregation in a dose-dependent manner (significant inhibition at 20 μM for HO-3089 and at 500 μM for the other agents; P <0.05), even if platelets were sensitized with heparin. However, their hindrance on platelet aggregation waned as the concentration of ADP rose (no effect at 40 μM ADP). PARP inhibitors had minimal effect on both collagen- and epinephrine-induced platelet aggregation. Our study first demonstrates the feasibility of a design for PARP inhibitors that does not only protect against ischemia-reperfusion-induced cardiac damage but may also prevent thrombotic events.",
keywords = "Antagonists, Coronary circulation, Platelets, Poly(ADP-ribose) polymerase inhibitors, Receptors, Thrombosis/embolism",
author = "Tamas Alexy and A. T{\'o}th and Zsolt Marton and B. Horv{\'a}th and Katalin Koltai and G. Feh{\'e}r and Gabor Kesmarky and T. Kalai and K. Hideg and B. S{\"u}megi and K. T{\'o}th",
year = "2004",
month = "3",
doi = "10.1097/00005344-200403000-00014",
language = "English",
volume = "43",
pages = "423--431",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors

AU - Alexy, Tamas

AU - Tóth, A.

AU - Marton, Zsolt

AU - Horváth, B.

AU - Koltai, Katalin

AU - Fehér, G.

AU - Kesmarky, Gabor

AU - Kalai, T.

AU - Hideg, K.

AU - Sümegi, B.

AU - Tóth, K.

PY - 2004/3

Y1 - 2004/3

N2 - Pathologic platelet activation has been implicated in the pathogenesis of ischemic heart disease. Since cardiomyocytes can be protected from ischemia-reoxygenation injury by poly(ADP-ribose) polymerase (PARP) inhibitors mimicking the adenine/ADP part of NAD+, their structural resemblance to ADP may also enable the blockade of platelet aggregation via binding to ADP receptors. Blood samples drawn from healthy volunteers were pre-incubated with different concentrations of PARP inhibitors: 4-hydroxyquinazoline, 2-mercapto-4(3H)-quinazolinone, or HO-3089. ADP-, collagen- and epinephrine-induced platelet aggregation was evaluated according to the method described by Born. The effect of PARP inhibitors on thrombocyte aggregation was also examined when platelets were sensitized by heparin and in the presence of incremental concentrations of ADP. All examined PARP inhibitors reduced the ADP-induced platelet aggregation in a dose-dependent manner (significant inhibition at 20 μM for HO-3089 and at 500 μM for the other agents; P <0.05), even if platelets were sensitized with heparin. However, their hindrance on platelet aggregation waned as the concentration of ADP rose (no effect at 40 μM ADP). PARP inhibitors had minimal effect on both collagen- and epinephrine-induced platelet aggregation. Our study first demonstrates the feasibility of a design for PARP inhibitors that does not only protect against ischemia-reperfusion-induced cardiac damage but may also prevent thrombotic events.

AB - Pathologic platelet activation has been implicated in the pathogenesis of ischemic heart disease. Since cardiomyocytes can be protected from ischemia-reoxygenation injury by poly(ADP-ribose) polymerase (PARP) inhibitors mimicking the adenine/ADP part of NAD+, their structural resemblance to ADP may also enable the blockade of platelet aggregation via binding to ADP receptors. Blood samples drawn from healthy volunteers were pre-incubated with different concentrations of PARP inhibitors: 4-hydroxyquinazoline, 2-mercapto-4(3H)-quinazolinone, or HO-3089. ADP-, collagen- and epinephrine-induced platelet aggregation was evaluated according to the method described by Born. The effect of PARP inhibitors on thrombocyte aggregation was also examined when platelets were sensitized by heparin and in the presence of incremental concentrations of ADP. All examined PARP inhibitors reduced the ADP-induced platelet aggregation in a dose-dependent manner (significant inhibition at 20 μM for HO-3089 and at 500 μM for the other agents; P <0.05), even if platelets were sensitized with heparin. However, their hindrance on platelet aggregation waned as the concentration of ADP rose (no effect at 40 μM ADP). PARP inhibitors had minimal effect on both collagen- and epinephrine-induced platelet aggregation. Our study first demonstrates the feasibility of a design for PARP inhibitors that does not only protect against ischemia-reperfusion-induced cardiac damage but may also prevent thrombotic events.

KW - Antagonists

KW - Coronary circulation

KW - Platelets

KW - Poly(ADP-ribose) polymerase inhibitors

KW - Receptors

KW - Thrombosis/embolism

UR - http://www.scopus.com/inward/record.url?scp=10744224018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224018&partnerID=8YFLogxK

U2 - 10.1097/00005344-200403000-00014

DO - 10.1097/00005344-200403000-00014

M3 - Article

VL - 43

SP - 423

EP - 431

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -